The VMVN Study: Virological Monitoring in Viet Nam (VMVN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01317498|
Recruitment Status : Completed
First Posted : March 17, 2011
Last Update Posted : August 3, 2018
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|HIV Infection AIDS||Other: Standard Care Other: Virological Monitoring||Not Applicable|
The optimal strategy for monitoring antiretroviral therapy (ART) in resource-limited settings (RLS) is unknown. In developed countries, routine monitoring with CD4 count and viral load (VL) testing is standard practice. In RLS, however, limitations in the availability of the technology for VL testing, and in financial resources to pay for VL testing, mean that few developing countries provide VL testing as part of the routine monitoring of patients on ART. Instead, ART is monitored primary by clinical examination with CD4 testing where available. This strategy has been endorsed by the most recent WHO guidelines for ART (WHO, 2010).
Standard laboratory monitoring of patients on ART in Vietnam includes CD4 testing every 6 months, where available. In many rural areas of the country, CD4 testing is not available and only clinical monitoring is used.
In this study we will test the hypothesis that routine viral monitoring every 6 months for patients on first-line ART will result in significantly higher rates of virological suppression and decrease the incidence of death or new or recurrent AIDS-defining illnesses by 50% within three years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||650 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effect of Routine Viral Load Monitoring on Clinical and Immunological Outcomes and Antiretroviral Drug Resistance on Patients Taking First-line Antiretroviral Drugs in Vietnam|
|Actual Study Start Date :||April 2011|
|Actual Primary Completion Date :||June 30, 2018|
|Actual Study Completion Date :||June 30, 2018|
Placebo Comparator: Standard Monitoring
The patients in the standard monitoring arm will receive routine laboratory monitoring as provided to all patients in public HIV clinics in Vietnam, including CD4 count, complete blood count, and liver functions tests every 6 months.
Other: Standard Care
CD4, liver function and CBC every 6 months
Active Comparator: Virological Monitoring
The patients in the virological monitoring arm will have routine laboratory monitoring as in the standard monitoring arm and in addition will have a viral load test performed every 6 months while in treatment. The first test will be done 6 months after initiating ART.
Other: Virological Monitoring
Viral Load test every 6 months
- Death or new/recurrent AIDS-Defining (WHO Clinical Stage IV) Illnesses [ Time Frame: 3 years ]The number of deaths and/or new/recurrent WHO Clinical Stage IV clinical illnesses that occur over 3 years of follow-up in each group.
- Virological Suppression [ Time Frame: 3 years ]The percentage of patients in each group who are still on treatment at 3 years who have virological suppression, defined as an HIV viral load below the level of laboratory detection.
- Time to identification and diagnosis of treatment failure. [ Time Frame: 3 years ]To calculate the difference in times in the 2 groups from the first emergence of active viral replication (defined as a detectable viral load) to identification and diagnosis of treatment failure.
- Time from virological treatment failure to switch to second line ART. [ Time Frame: 3 years ]We will calculate the mean time from virological treatment failure to switch to second line ART in both groups.
- Resistance mutations [ Time Frame: 3 years ]The difference in resistance mutation patterns at the diagnosis of virological treatment failure in each group.
- Sensitivity and specificity of WHO criteria for treatment failure [ Time Frame: 3 years ]To determine the sensitivity and specificity of WHO criteria for treatment failure among patients on first-line ARV in Vietnam.
- Cost-benefit analysis [ Time Frame: 3 years ]To evaluate and compare the costs and benefits of adding routine VL testing to standard laboratory monitoring for patients on first-line ART in Vietnam. In the event that the trial shows a benefit in the primary outcome of decreased number of deaths plus WHO Stage 4 clinical events, the analysis will evaluate the cost per life saved and the cost per outcome event avoided. The analysis will also include a cost per quality-adjusted life year saved.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age >= 18
- Confirmed HIV infection
- Not currently taking ART
- Meets Vietnam MOH criteria for ART (THROUGH OCTOBER 2011:CD4<250 cells/mm3, WHO Clinical Stage IV, or WHO clinical stage III with CD4<350 cells/mm3; FROM NOVEMBER 2011: CD4<350 cells/mm3, OR WHO Clinical Stage III or IV)
- Completes required Vietnam MOH ART adherence training
- Signs written informed consent form
- Any ART use within the previous 3 months
- History of treatment failure on first-line ART or known resistance to first-line ART.
- Unable or unwilling to give written informed consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01317498
|Bach Mai Hospital|
|Principal Investigator:||Todd M Pollack, MD||Beth Israel Deaconess Medical Center|
|Principal Investigator:||Pham T Thuy, MD, PhD||Bach Mai Hospital, Hanoi, Vietnam|
|Principal Investigator:||Julian Elliott, MBBS, PhD||Alfred Hospital, Melbourne, Australia|
|Principal Investigator:||Donn J Colby, MD, MPH||Center for Applied Research on Men and Health|
|Responsible Party:||Todd Pollack, Assistant Professor in Medicine, Part-time, Beth Israel Deaconess Medical Center|
|Other Study ID Numbers:||
|First Posted:||March 17, 2011 Key Record Dates|
|Last Update Posted:||August 3, 2018|
|Last Verified:||August 2018|
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
RNA Virus Infections
Immunologic Deficiency Syndromes
Immune System Diseases